Search research articles
Contact Us
Filters
Showing results (41-50 of 49) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 49 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1986
Phase I study of intravenous menogaril administered intermittently
P Dodion, C Sessa, R Joss, et al.
European Journal of Cancer & Clinical Oncology
|
June 1, 1986
Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent--a phase II study of the EORTC early clinical trials group
U Bruntsch, P Dodion, W W Ten Bokkel Huinink, et al.
European Journal of Cancer & Clinical Oncology
|
June 1, 1988
Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days
P Dodion, D de Valeriola, N Crespeigne, et al.
Cancer
|
September 15, 1987
Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck
M Clavel, F Cognetti, P Dodion, et al.
Cancer
|
January 15, 1989
Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis
G Schwartsmann, E Bork, J B Vermorken, et al.
Investigational New Drugs
|
January 1, 1990
Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma
S B Kaye, M Clavel, P Dodion, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1990
Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies
G Schwartsmann, P Dodion, J B Vermorken, et al.
European Journal of Cancer & Clinical Oncology
|
December 1, 1989
Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study
G Schwartsmann, W J van der Vijgh, M B van Hennik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 6, 2012
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma
M M Mita, E Poplin, C D Britten, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 49) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 49 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1986
Phase I study of intravenous menogaril administered intermittently
P Dodion, C Sessa, R Joss, et al.
European Journal of Cancer & Clinical Oncology
|
June 1, 1986
Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent--a phase II study of the EORTC early clinical trials group
U Bruntsch, P Dodion, W W Ten Bokkel Huinink, et al.
European Journal of Cancer & Clinical Oncology
|
June 1, 1988
Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days
P Dodion, D de Valeriola, N Crespeigne, et al.
Cancer
|
September 15, 1987
Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck
M Clavel, F Cognetti, P Dodion, et al.
Cancer
|
January 15, 1989
Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis
G Schwartsmann, E Bork, J B Vermorken, et al.
Investigational New Drugs
|
January 1, 1990
Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma
S B Kaye, M Clavel, P Dodion, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1990
Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies
G Schwartsmann, P Dodion, J B Vermorken, et al.
European Journal of Cancer & Clinical Oncology
|
December 1, 1989
Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study
G Schwartsmann, W J van der Vijgh, M B van Hennik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 6, 2012
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma
M M Mita, E Poplin, C D Britten, et al.
Page
of 5